Siglec-15, which selectively drives immunosuppression in the tumor microenvironment, has emerged as a viable therapeutic target. In a phase I trial of NC318, a Siglec-15 antibody, encouraging efficacy was seen, including a complete response in non-small cell lung cancer refractory to PD-1 blockade.

中文翻译：

---

Siglec-15：有吸引力的免疫疗法靶标。

在肿瘤微环境中选择性驱动免疫抑制的Siglec-15已经成为可行的治疗靶标。在NC318的Siglec-15抗体的I期试验中，看到了令人鼓舞的功效，包括难治性PD-1阻断的非小细胞肺癌的完全应答。